{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Victoza%C2%AE", "query": { "intervention": "Victoza®" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 15, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Victoza%C2%AE&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T18:44:51.263Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03795701", "title": "To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "Saxenda®", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Texas Tech University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 73, "start_date": "2019-01-08", "completion_date": "2022-05-01", "has_results": false, "last_update_posted_date": "2023-12-04", "last_synced_at": "2026-09-08T18:44:51.263Z", "location_count": 2, "location_summary": "Lubbock, Texas", "locations": [ { "city": "Lubbock", "state": "Texas" }, { "city": "Lubbock", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03795701" }, { "nct_id": "NCT03799198", "title": "Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "Weight Management Program (WMP)", "type": "OTHER" }, { "name": "Medication for chronic weight management (Rx)", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2019-01-07", "completion_date": "2020-05-22", "has_results": true, "last_update_posted_date": "2022-11-14", "last_synced_at": "2026-09-08T18:44:51.263Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03799198" }, { "nct_id": "NCT02730377", "title": "Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "liraglutide", "type": "DRUG" }, { "name": "alpha-glucosidase inhibitors", "type": "DRUG" }, { "name": "DPP-4 inhibitors", "type": "DRUG" }, { "name": "meglitinides", "type": "DRUG" }, { "name": "SGLT-2 inhibitors", "type": "DRUG" }, { "name": "sulphonylurea", "type": "DRUG" }, { "name": "thiazolidinediones", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1991, "start_date": "2016-03-28", "completion_date": "2019-08-12", "has_results": true, "last_update_posted_date": "2020-07-07", "last_synced_at": "2026-09-08T18:44:51.263Z", "location_count": 179, "location_summary": "Birmingham, Alabama • Haleyville, Alabama • Tuscumbia, Alabama + 157 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Haleyville", "state": "Alabama" }, { "city": "Tuscumbia", "state": "Alabama" }, { "city": "Fountain Hills", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02730377" }, { "nct_id": "NCT03757130", "title": "Multiple Ascending Dose Study of AMG 598 in Adults With Obesity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "AMG 598", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Liraglutide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 50, "start_date": "2018-11-26", "completion_date": "2019-12-16", "has_results": true, "last_update_posted_date": "2023-09-14", "last_synced_at": "2026-09-08T18:44:51.263Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Tustin, California • South Miami, Florida + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tustin", "state": "California" }, { "city": "South Miami", "state": "Florida" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03757130" }, { "nct_id": "NCT01658501", "title": "Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "50 mg PB1023", "type": "DRUG" }, { "name": "70 mg PB1023", "type": "DRUG" }, { "name": "100 mg PB1023", "type": "DRUG" }, { "name": "Placebo (0.9% Sodium Chloride)", "type": "DRUG" }, { "name": "Victoza®", "type": "DRUG" }, { "name": "Diet and Exercise", "type": "OTHER" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Sulfonylurea", "type": "DRUG" }, { "name": "Metformin and Sulfonylurea", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "PhaseBio Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 593, "start_date": "2012-07", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2015-12-07", "last_synced_at": "2026-09-08T18:44:51.263Z", "location_count": 93, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Gulf Shores", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01658501" }, { "nct_id": "NCT01117350", "title": "Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin glargine", "type": "DRUG" }, { "name": "Liraglutide", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "35 Years to 75 Years" }, "enrollment_count": 978, "start_date": "2010-07", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2014-04-11", "last_synced_at": "2026-09-08T18:44:51.263Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01117350" }, { "nct_id": "NCT07325435", "title": "Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes (T2DM)" ], "interventions": [ { "name": "SGLT-2 inhibitor", "type": "DRUG" }, { "name": "GLP1-RA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MaryAnn Banerji", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "24 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "24 Years to 80 Years" }, "enrollment_count": 60, "start_date": "2024-12-21", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-09-08T18:44:51.263Z", "location_count": 1, "location_summary": "Brooklyn, New York", "locations": [ { "city": "Brooklyn", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07325435" }, { "nct_id": "NCT01388361", "title": "Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "insulin degludec", "type": "DRUG" }, { "name": "insulin aspart", "type": "DRUG" }, { "name": "liraglutide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 413, "start_date": "2011-09", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2017-03-06", "last_synced_at": "2026-09-08T18:44:51.263Z", "location_count": 48, "location_summary": "Concord, California • La Jolla, California • Lancaster, California + 44 more", "locations": [ { "city": "Concord", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "National City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01388361" }, { "nct_id": "NCT01676116", "title": "The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "insulin degludec/liraglutide", "type": "DRUG" }, { "name": "liraglutide", "type": "DRUG" }, { "name": "exenatide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 438, "start_date": "2012-08-29", "completion_date": "2014-03-11", "has_results": true, "last_update_posted_date": "2019-01-03", "last_synced_at": "2026-09-08T18:44:51.263Z", "location_count": 85, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Mesa, Arizona + 73 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Concord", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01676116" }, { "nct_id": "NCT00781937", "title": "Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metabolism and Nutrition Disorder", "Obesity" ], "interventions": [ { "name": "liraglutide", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 422, "start_date": "2008-10-30", "completion_date": "2010-09-01", "has_results": true, "last_update_posted_date": "2017-11-01", "last_synced_at": "2026-09-08T18:44:51.263Z", "location_count": 27, "location_summary": "Goodyear, Arizona • Peoria, Arizona • Huntington Beach, California + 22 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Montclair", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00781937" } ] }